Jennison Associates
CRVS icon

Jennison Associates’s Corvus Pharmaceuticals CRVS Stock Holding History

Jennison Associates’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-466,724
Closed -$4.83M – 667
2017
Q4 		$4.83M Sell
466,724
-425,927
-48% -$5.45M ﹤0.01% 497
2017
Q3 		$14.2M Sell
892,651
-126,362
-12% -$1.75M 0.01% 447
2017
Q2 		$12.3M Buy
1,019,013
+475,164
+87% +$5.07M 0.01% 458
2017
Q1 		$11.3M Sell
543,849
-26,352
-5% -$413K 0.01% 481
2016
Q4 		$8.15M Buy
570,201
+874
+0.2% +$13.3K 0.01% 493
2016
Q3 		$9.37M Sell
569,327
-1,154
-0.2% -$16.6K 0.01% 479
2016
Q2 		$8.07M Buy
570,481
+106,349
+23% +$1.44M 0.01% 479
2016
Q1 		$6.58M Buy
+464,132
New +$6.66M 0.01% 479

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return